Skip to main content
COGNITION THERAPEUTICS INC logo

COGNITION THERAPEUTICS INC — Investor Relations & Filings

Ticker · CGTX ISIN · US19243B1026 US Professional, scientific and technical activities
Open in API
Filings indexed 281 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country US United States of America
Listing US CGTX

About COGNITION THERAPEUTICS INC

https://cogrx.com/

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company that discovers and develops oral, small-molecule therapeutics for neurodegenerative disorders. The company's primary focus is on conditions such as Alzheimer's disease and Dementia with Lewy Bodies (DLB). Its therapeutic approach is centered on developing medications designed to target and modulate key cellular damage response mechanisms. By aiming to rescue trafficking deficits and restore normal cellular housekeeping functions, the company seeks to protect neurons, improve synaptic health, and ultimately address the cognitive decline associated with these diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 8-K “Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934,” reporting Other Events and filing exhibits. It contains no substantive financial statements but is a regulatory disclosure filing. Under our taxonomy, standalone SEC filings such as Form 8-K are classified as Regulatory Filings (RNS).
2026-05-21 English
10-Q - COGNITION THERAPEUTICS INC (0001455365) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-08 English
S-8 - COGNITION THERAPEUTICS INC (0001455365) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Cognition Therapeutics, Inc. on March 26, 2026. Form S-8 is used to register securities to be offered under employee benefit plans, such as equity incentive plans. The document includes details about the registration of additional shares under the company's 2021 Equity Incentive Plan, references to prior Form S-8 filings, and incorporates by reference the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025. It also contains exhibits such as the certificate of incorporation, bylaws, legal opinions, and consents. The document is a registration statement related to capital raising through equity incentive plans, not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including registration of shares for employee plans.
2026-03-26 English
10-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
Annual Report FY 2025
2026-03-26 English
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2026, by Cognition Therapeutics, Inc. It reports the issuance of a press release announcing financial results for the year ended December 31, 2025, and includes an investor presentation. The Form 8-K is a current report used to announce major events or updates, including earnings releases. The key section is Item 2.02 "Results of Operations and Financial Condition," which indicates the company issued a press release with financial results. The document itself is not the full earnings release but a filing to announce and furnish the press release and presentation. Given the document length (4888 characters) and content, it is primarily an earnings release announcement via Form 8-K. According to the rules, the initial announcement of quarterly or periodical financial results (key highlights only) is classified as Earnings Release (ER). The Form 8-K is the vehicle for this announcement. Therefore, the filing type is ER with high confidence.
2026-03-26 English
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes standard Form 8-K headings, such as Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). It mentions a press release about advancing development of a drug, but does not contain financial statements or detailed financial data. The document length is 3715 characters, which is relatively short and consistent with a current report rather than a full financial report. There is no indication of an earnings release, annual report, or other detailed financial disclosures. Therefore, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-03-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.